

Biogen beats Q3 estimates, narrows FY2026 EPS outlook, and sees analysts raise price targets to $290; shares dip 0.3% premarket.
You can purchase shares of Biogen (NASDAQ:BIIB) through any online brokerage.
Other companies in Biogen’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Biogen has a consensus price target of $246.32.
The stock price for Biogen (NASDAQ: BIIB) is $248.35 last updated November 6, 2026 at 4:00 PM EST.
There are no upcoming dividends for Biogen.
Biogen does not have any upcoming earnings scheduled.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also...